| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | Chief Operating Officer | Stock Option (right to buy) | 115,000 | 26 Apr 2023 | Direct | ||
| Fulcrum Therapeutics, Inc. | Chief Operating Officer | No securities are beneficially owned | 0 | 09 Aug 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | 26 Apr 2023 | 1 | $0 | 4 | Chief Operating Officer | 28 Apr 2023, 16:17 |
| FULC | Fulcrum Therapeutics, Inc. | 09 Feb 2023 | 1 | $0 | 4 | Chief Operating Officer | 13 Feb 2023, 15:15 |
| FULC | Fulcrum Therapeutics, Inc. | 09 Aug 2022 | 1 | $0 | 4 | Chief Operating Officer | 11 Aug 2022, 16:15 |
| FULC | Fulcrum Therapeutics, Inc. | 09 Aug 2022 | 0 | $0 | 3 | Chief Operating Officer | 11 Aug 2022, 16:10 |